发明公开
- 专利标题： CONDENSED PYRIDINE COMPOUND
- 专利标题（中）： KONDENSIERTE PYRIDINVERBINDUNG
-
申请号： EP08703164.7申请日： 2008-01-11
-
公开(公告)号： EP2123651A1公开(公告)日： 2009-11-25
- 发明人: SHIRAKAMI, Shohei , INOUE, Takayuki , MUKOYOSHI, Koichiro , NAKAJIMA, Yutaka , USUDA, Hiroyuki , HAMAGUCHI, Hisao , HIGASHI, Yasuyuki , HATANAKA, Keiko
- 申请人： Astellas Pharma Inc.
- 申请人地址： 3-11, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 专利权人： Astellas Pharma Inc.
- 当前专利权人： Astellas Pharma Inc.
- 当前专利权人地址： 3-11, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 代理机构： Gille, Christian
- 优先权： JP2007005236 20070112
- 国际公布： WO2008084861 20080717
- 主分类号： C07D471/04
- IPC分类号： C07D471/04 ; A61K31/437 ; A61K31/4545 ; A61K31/497 ; A61K31/501 ; A61K31/506 ; A61K31/55 ; A61P29/00 ; A61P37/00 ; A61P37/02 ; A61P43/00 ; C07D471/14
摘要：
The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases.
As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention.
More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).
As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention.
More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).
信息查询
